Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Mar 1;15(1):27.
doi: 10.1038/s41408-025-01224-w.

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML

Francesco Mannelli  1   2   3 , Matteo Piccini  4 , Marco Frigeni  5 , Giacomo Gianfaldoni  4 , Sara Bencini  6 , Silvia Salmoiraghi  5 , Barbara Scappini  4 , Benedetta Peruzzi  6 , Roberto Caporale  6 , Gaia Ciolli  7   4 , Francesca Crupi  7   4   8 , Laura Fasano  7   4 , Elisa Quinti  7   4 , Andrea Pasquini  7   4 , Jessica Caroprese  7   4   8 , Fiorenza Vanderwert  4   8 , Giada Rotunno  4   8 , Fabiana Pancani  4   8 , Leonardo Signori  7   4   8 , Danilo Tarantino  4   8 , Chiara Maccari  4   8 , Francesco Annunziato  7   6 , Orietta Spinelli  5 , Paola Guglielmelli  7   4   8 , Alessandro Rambaldi  5   9 , Alessandro M Vannucchi  7   4   8
Affiliations

Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML

Francesco Mannelli et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Analysis of survival and time to hematopoietic recovery according to NGS status.
Disease-free survival (A) and overall survival (B) according to the presence of mutations by NGS. Box plots illustrate the distribution of time to neutrophil ≥ 0.5 × 109/L (C) and platelet count ≥20 × 109/L (E) according to NGS and number of anthracyclines-containing cycles (0–1 versus 2). Cumulative incidence of recovery for neutrophil ≥0.5 × 109/L (D) and platelet count ≥20 × 109/L (F) for NGS+ patients receiving two cycles with anthracyclines (red curve) and other categories merged (blue curve). The curves of patients with no mutations (NGSwt) are depicted in blue; the curves of patients with at least one mutation (NGS+) are depicted in red. HR: hazard ratio; 95% CI: confidence interval. Box plots and cumulative incidence plots were generated by R software. Boxes represent the interquartile range containing 50% of the cases; the horizontal line marks the median; dots are single cases. KW Kruskal–Wallis test.
See this image and copyright information in PMC

References

    1. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. The International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphological, clinical, and genomic data. Blood. 2022;140:1200–28. - PMC - PubMed
    1. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36:1703–19. - PMC - PubMed
    1. Green CL, Koo KK, Hills RK, Burnett AK, Linch DC, Gale RE. Prognostic significance of CEBPA mutations in a Large Cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol. 2010;28:2739–47. - PubMed
    1. Dufour A, Schneider F, Metzeler KH, Hoster E, Schneider S, Zellmeier E, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28:570–7. - PubMed
    1. Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139:87–103. - PubMed